Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Net Income towards Common Stockholders (2023 - 2025)

Historic Net Income towards Common Stockholders for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Q3 2025 value amounting to -$9.8 million.